Results of a phase IIa clinical trial of an anti-inflammatory molecule,chaperonin 10,in multiple sclerosis

Abstract

Background

Chaperonin 10 (Cpn10) is a mitochondrial molecule involved in protein folding. The aim of this study was to determine the safety profile of Cpn10 in patients with multiple sclerosis (MS).

Methods

A total of 50 patients with relapse-remitting or secondary progressive MS were intravenously administered 5 mg or 10 mg of Cpn10 weekly for 12 weeks in a double-blind, randomized, placebo controlled, phase II trial. Clinical reviews, including Expanded Disability Status Scale and magnetic resonance imaging (MRI) with Gadolinium, were undertaken every 4 weeks. Stimulation of patient peripheral blood mononuclear cells with lipopolysaccharide ex vivo was used to measure the in vivo activity of Cpn10.

Results

No significant differences in the frequency of adverse events were seen between treatment and placebo arms. Leukocytes from both groups of Cpn10-treated patients produced significantly lower levels of critical proinflammatory cytokines. A trend toward improvement in new Gadolinium-enhancing lesions on MRI was observed, but this difference was not statistically significant. No differences in clinical outcome measures were seen.

Conclusions

Cpn10 is safe and well tolerated when administered to patients with MS for 3 months, however, a further extended phase II study primarily focused on efficacy is warranted.

Keywords

chaperonin 10 clinical trial heat shock proteins multiple sclerosis [41]randomized controlled (CONSORT agreement)treatment

Get full access to this article

View all access options for this article.

References

1 Compston A Coles A . Multiple sclerosis. Lancet 2002; 359: 1221–1231.

2 Barnett MH Prineas JW . Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458–468.

3 Massacesi L Parigi A Barilaro A . Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 2005; 62: 1843–1847.

4 Hartung HP Gonsette R Konig N . Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018–2025.

5 Johnson KP Brooks BR Cohen JA . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268–1276.

6 Jacobs LD Cookfair DL Rudick RA . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285–294.

7 Beck RW Cleary PA Anderson MM . A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581–588.

8 Polman CH O'Connor PW Havrdova E . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

9 Harness J Cavanagh A Morton H McCombe P . A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. J Neurol Sci 2003; 216: 33–41.

10.

10 Zhang B Harness J Somodevilla-Torres MJ . Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139–151. J Neurol Sci 2000; 182: 5–15.

11.

11 Mehta AR Eessalu TE . Aggarwal BB purification and characterization of early pregnancy factor from human pregnancy sera. J Biol Chem 1989; 264: 2266–2271.

12.

12 Ohashi K Burkart V Flohe S Kolb H . Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558–561.

13.

13 Vabulas RM Ahmad-Nejad P da Costa C . Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276: 31332–31339.

14.

14 Johnson BJ Le TT Dobbin CA . Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem 2005; 280: 4037–4047.

15.

15 Zhang B Walsh MD Nguyen KB . Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expression in the spinal cord of SJL/J mice with experimental autoimmune encephalomyelitis and the delayed-type hypersensitivity reaction to trinitrochlorobenzene in normal BALB/c mice. J Neurol Sci 2003; 212: 37–46.

16.

16 Athanasas-Platsis S Zhang B Hillyard NC . Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis. J Neurol Sci 2003; 214: 27–36.

17.

17 McCombe PA . Recombinant EPF/chaperonin 10 promotes the survival of O4-positive pro-oligodendrocytes prepared from neonatal rat brain. Cell Stress Chaperones 2008; 13: 467–474.

18.

18 Broadley SA Johnson B Feeney D Shakib S . Phase 1a and 1b clinical trials of chaperonin 10 in healthy volunteers and patients with multiple sclerosis. J Neurol Sci 2005; 238: S223.

19.

19 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

20.

20 Paty DW Oger JJ Kastrukoff LF . MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 180–185.

21.

21 Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

22.

22 Hobart J Lamping D Fitzpatrick R Riazi A Thompson A . The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124: 962–973.

23.

23 Vanags D Williams B Johnson B . Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006; 368: 855–863.

24.

24 Tasker SA Treanor JJ Paxton WB Wallace MR . Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 430–433.

25.

25 Williams B Vanags D Hall S . Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indication. Arch Dermatol 2008; 144: 683–685.

26.

26 PRISMS . Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498–1504.